Annual report pursuant to Section 13 and 15(d)

Note 4 - Fair Value Measurements (Details Textual)

v3.10.0.1
Note 4 - Fair Value Measurements (Details Textual) - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended
Jun. 30, 2018
Mar. 31, 2017
Jun. 30, 2018
Jun. 30, 2017
Jun. 30, 2016
Aug. 01, 2016
Mar. 14, 2016
Business Combination, Liabilities Arising from Contingencies, Amount Recognized $ 0   $ 0        
Payment for Contingent Consideration Liability     88,500 $ 28,500      
Payment for Contingent Consideration Liability, Financing Activities     61,900 20,316    
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability     (26,600) (11,800)    
Payment for Contingent Consideration Liability, Operating Activities       11,800      
CyVek, Inc. [Member]              
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High 35,000   35,000        
Business Combination, Liabilities Arising from Contingencies, Amount Recognized 35,000   35,000        
Zephyrus [Member]              
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High 7,000   7,000       $ 7,000
Business Combination, Liabilities Arising from Contingencies, Amount Recognized 6,500   6,500        
Payment for Contingent Consideration Liability       3,500      
Payment for Contingent Consideration Liability, Financing Activities 3,500 $ 3,500          
Advanced Cell Diagnostics (ACD) [Member]              
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High 75,000   75,000     $ 75,000  
Business Combination, Liabilities Arising from Contingencies, Amount Recognized 37,000   37,000        
Payment for Contingent Consideration Liability       $ 25,000      
Advance Cell Diagnostics (ACD), Zephyrus, and CyVek Inc.[Member]              
Business Combination, Liabilities Arising from Contingencies, Amount Recognized $ 78,500   $ 78,500